Empagliflozin in carotid intima-media thickness

To compare the carotid intima-media thickness in ultrasound of type II diabetic patients with myocardial infarction requiring primary angioplasty in two groups receiving empagliflozin and placebo.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230727058945N1

Enrollment

Registered

2023-08-23

Start date

2023-08-13

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: myocardial infarction. Condition 2: Type 2 diabetes. ST elevation (STEMI) myocardial infarction of unspecified site Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: in this group, 40 type 2 diabetic patients treated with oral drugs, will recieve Empagliflozin from Abidi Pharmaceutical Company in the form of 10 mg tablets,once a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: type 2 diabetic patients with a history of glucose reducing medications patients with STEMI with ST-segment elevation more than 0.1mv in two or more leads in ECG

Exclusion criteria

Exclusion criteria: cardiogenic shock hypoglycemia diabetic ketoacidosis history of coronary artery bypass surgery type 1 diabetes severe liver failure advanced cancer patients history of allergy to Empagliflozin or ingredients severe renal failure, ESRD, or dialysis hypovolemia inflammatory diseases Cancer history advanced heart failure patients under 18 years of age pregnancy

Design outcomes

Primary

Measure	Time frame
Carotid intima-media thickness. Timepoint: Measurement of intima media thickness of carotid artery at the beginning of the study (before the intervention) and 3 months after the start of drug use. Method of measurement: B-mode and Doppler ultrasound.;Carotid resistivity index. Timepoint: Measurement of the carotid artery resistivity index at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.;Atherosclerotic plaques. Timepoint: Measurement of atherosclerotic plaques at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.	—

Measure

Time frame

Carotid intima-media thickness. Timepoint: Measurement of intima media thickness of carotid artery at the beginning of the study (before the intervention) and 3 months after the start of drug use. Method of measurement: B-mode and Doppler ultrasound.;Carotid resistivity index. Timepoint: Measurement of the carotid artery resistivity index at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.;Atherosclerotic plaques. Timepoint: Measurement of atherosclerotic plaques at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Sabat Sani

Zanjan University of Medical Sciences

Hs742022@gmail.com+98 44 3365 4571

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026